Lymphocyte gene therapy
KW Culver, WF Anderson, RM Blaese - Human gene therapy, 1991 - liebertpub.com
KW Culver, WF Anderson, RM Blaese
Human gene therapy, 1991•liebertpub.comGenetically corrected T cells are currently under investigation as a treatment for severe
combined immunodeficiency disease resulting from a lack of adenosine deaminase (ADA).
Monthly injections of these ADA-corrected T cells have resulted in measurable ADA activity
in the peripheral blood and the in vivo production of antibody to blood group antigen.
Genetically corrected T cells appear to be clinically valuable vehicles for gene therapy.
combined immunodeficiency disease resulting from a lack of adenosine deaminase (ADA).
Monthly injections of these ADA-corrected T cells have resulted in measurable ADA activity
in the peripheral blood and the in vivo production of antibody to blood group antigen.
Genetically corrected T cells appear to be clinically valuable vehicles for gene therapy.
Abstract
Genetically corrected T cells are currently under investigation as a treatment for severe combined immunodeficiency disease resulting from a lack of adenosine deaminase (ADA). Monthly injections of these ADA-corrected T cells have resulted in measurable ADA activity in the peripheral blood and the in vivo production of antibody to blood group antigen. Genetically corrected T cells appear to be clinically valuable vehicles for gene therapy.
Mary Ann Liebert